Viral Infection Study

Effect of short term inhaled Budesonide in children with mild COVID 19 infection an open labeled randomized controlled trial - NA

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2021/06/034327

Enrollment

150

Registered

2021-06-21

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: Budesonide 400 mcg: twice daily for 7 days Control Intervention1: Standard of Care: Vitamin C and zinc supplements once daily for 14 days

Eligibility

Inclusion criteria

Inclusion criteria: Confirmed diagnosis of COVID 19 infection(COVID RT-PCR positive or HRCT suggestive of CORADS 4/5/6) Mild disease presenting within the first 7 days of illness

Exclusion criteria

Exclusion criteria: Children with moderate or severe COVID 19 infection at presentation. Children with comorbidities on immunosuppressants or on steroids. Parents or guardian not consenting to be part of the study.

Design outcomes

Primary

Measure	Time frame
Effect on disease progression in children affected with COVID 19Timepoint: 14 days	—

Secondary

Measure	Time frame
Effect on symptom controlTimepoint: 14 days	—

Countries

India

Contacts

Public ContactDr Ayesha Mariam

Apollo Childrenâ??s Hospital

ayesha.mariam@yahoo.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026